Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 4/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544561 | 0.92 | MET (0.34) | PIK3CAMTORTGFBR1THRBMAPK14 | |
| SCHEMBL29544735 | 0.82 | CCNT1 (0.34) | PIK3CAMTORPARP1 | |
| SCHEMBL29544652 | 0.81 | NCF1 (0.36) | TGFBR1 | |
| SCHEMBL29544372 | 0.81 | GRM2 (0.36) | GRM2 | |
| SCHEMBL29544338 | 0.81 | GRM2 (0.36) | GRM2 | |
| SCHEMBL29544753 | 0.80 | CCNC (0.36) | PARP1TGFBR1THRBMAPK14 | |
| SCHEMBL29544881 | 0.80 | ATM (0.38) | — | |
| SCHEMBL29545042 | 0.79 | PIM1 (0.36) | — | |
| SCHEMBL29545041 | 0.79 | PIM1 (0.36) | — | |
| SCHEMBL29544663 | 0.79 | RIPK3 (0.36) | PIK3CAMTORGSK3BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |